| abstract |
(I) A pharmaceutical composition for use in the treatment of a disease or condition associated with bone cancer metastasis comprises a compound of formula (I) or a salt, metabolite, solvate or prodrug thereof wherein each of X and Y is independently O, NR5 or S; R is H or C(=O)C1-C8alkyl; R1, R2 and R3 are independently H, methyl or (CH2)m-CH3; R4 is NR5R6, OR5, OC(=O)R7, C(=O)OR5, C(=O)R5, C(=O)NR5R6, halogen, 5- or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl or glucosyl; each of R5 and R6 is independently H or C1-C8alkyl; R7 is C1-C8alkyl, OR5 or NR5R6; m is 1-12; and n is 1-12. A pharmaceutical composition for use in the inhibition of hypercalcemia, for use in the inhibition of bone resorption or for use in the treatment of osetolytic lesions comprising a compound of formula (I) is also outlined. Preferably the compound is 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-enone. |